 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (January 2016) |
| Company type | Public |
|---|---|
| Nasdaq: PHIO | |
| Industry | Biotechnology |
| Founded | 2011 |
| Headquarters | Marlborough, Ma. |
Key people | Robert Bitterman (president and CEO) |
| Website | www |
Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.[1]
- ^ "After name change, Phio Pharma 'reinvents' gene-silencing pipeline". www.bizjournals.com. Retrieved 2022-04-13.